CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 201 enrolled
Drug / intervention
Abilify maintenadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03376763
NCT03376763Phase 4Completed
CompareCT.gov

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

Korea Otsuka Pharmaceutical Co., Ltd.·interventional·Posted Dec 18, 2017·Updated Dec 17, 2021

In Brief

A Phase 4 clinical trial evaluating Abilify maintena for Schizophrenia and 4 related conditions. Completed, enrolled 201 participants across 27 sites.

Detailed Summary

Interventional, multicenter, open-label, 20 weeks study * To identify efficacy and safety in switching from oral aripiprazole to Abilify Maintena. * To identify efficacy and safety in switching from oral atypical antipsychotics other than aripiprazole to Abilify Maintena

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Antipsychotics, Long-Acting Injection, LAI, Aripiprazole
CountriesSouth Korea
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 18, 2017
Enrollment StartNov 21, 2017
Primary CompletionNov 19, 2021
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 8.5 years ago

Interventions

Abilify maintenadrug

Switching from oral atypical antipsychotics to long-acting injectable aripiprazole (Abilify maintena)